|
|
| (2 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==Nukacin ISK-1 in inactive state== | | ==Nukacin ISK-1 in inactive state== |
| - | <StructureSection load='5z5r' size='340' side='right' caption='[[5z5r]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | + | <StructureSection load='5z5r' size='340' side='right'caption='[[5z5r]]' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[5z5r]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Staphylococcus_warneri Staphylococcus warneri]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5Z5R OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5Z5R FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5z5r]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Staphylococcus_warneri Staphylococcus warneri]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5Z5R OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5Z5R FirstGlance]. <br> |
| - | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAL:D-ALANINE'>DAL</scene>, <scene name='pdbligand=DBB:D-ALPHA-AMINOBUTYRIC+ACID'>DBB</scene>, <scene name='pdbligand=DBU:(2Z)-2-AMINOBUT-2-ENOIC+ACID'>DBU</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5z5r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5z5r OCA], [http://pdbe.org/5z5r PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5z5r RCSB], [http://www.ebi.ac.uk/pdbsum/5z5r PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5z5r ProSAT]</span></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DAL:D-ALANINE'>DAL</scene>, <scene name='pdbligand=DBB:D-ALPHA-AMINOBUTYRIC+ACID'>DBB</scene>, <scene name='pdbligand=DBU:(2Z)-2-AMINOBUT-2-ENOIC+ACID'>DBU</scene></td></tr> |
| | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5z5r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5z5r OCA], [https://pdbe.org/5z5r PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5z5r RCSB], [https://www.ebi.ac.uk/pdbsum/5z5r PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5z5r ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/LANNA_STAWA LANNA_STAWA]] Lanthionine-containing peptide antibiotic (lantibiotic) active on Gram-positive bacteria, such as Lactobacillus sakei, Leuconostoc mesenteroides and Pediococcus pentosaceus. The bactericidal activity of lantibiotics is based on depolarization of energized bacterial cytoplasmic membranes, initiated by the formation of aqueous transmembrane pores.<ref>PMID:16233732</ref> <ref>PMID:16957223</ref> [REFERENCE:4] | + | [https://www.uniprot.org/uniprot/LANNA_STAWA LANNA_STAWA] Lanthionine-containing peptide antibiotic (lantibiotic) active on Gram-positive bacteria, such as Lactobacillus sakei, Leuconostoc mesenteroides and Pediococcus pentosaceus. The bactericidal activity of lantibiotics is based on depolarization of energized bacterial cytoplasmic membranes, initiated by the formation of aqueous transmembrane pores.<ref>PMID:16233732</ref> <ref>PMID:16957223</ref> [REFERENCE:4] |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 22: |
Line 23: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| | + | [[Category: Large Structures]] |
| | [[Category: Staphylococcus warneri]] | | [[Category: Staphylococcus warneri]] |
| - | [[Category: Fujinami, D]] | + | [[Category: Fujinami D]] |
| - | [[Category: Kohda, D]] | + | [[Category: Kohda D]] |
| - | [[Category: Antibiotic]]
| + | |
| - | [[Category: Lantibiotic]]
| + | |
| Structural highlights
Function
LANNA_STAWA Lanthionine-containing peptide antibiotic (lantibiotic) active on Gram-positive bacteria, such as Lactobacillus sakei, Leuconostoc mesenteroides and Pediococcus pentosaceus. The bactericidal activity of lantibiotics is based on depolarization of energized bacterial cytoplasmic membranes, initiated by the formation of aqueous transmembrane pores.[1] [2] [REFERENCE:4]
Publication Abstract from PubMed
The lantibiotic nukacin ISK-1 exerts antimicrobial activity through binding to lipid II. Here, we perform NMR analyses of the structure of nukacin ISK-1 and the interaction with lipid II. Unexpectedly, nukacin ISK-1 exists in two structural states in aqueous solution, with an interconversion rate on a time scale of seconds. The two structures differ in the relative orientations of the two lanthionine rings, ring A and ring C. Chemical shift perturbation induced by the titration of lipid II reveals that only one state was capable of binding to lipid II. On the molecular surface of the active state, a multiple hydrogen-bonding site formed by amino acid residues in the ring A region is adjacent to a hydrophobic surface formed by residues in the ring C region, and we propose that these sites interact with the pyrophosphate moiety and the isoprene chain of the lipid II molecule, respectively.
The lantibiotic nukacin ISK-1 exists in an equilibrium between active and inactive lipid-II binding states.,Fujinami D, -Mahin AA, Elsayed KM, Islam MR, Nagao JI, Roy U, Momin S, Zendo T, Kohda D, Sonomoto K Commun Biol. 2018 Sep 25;1:150. doi: 10.1038/s42003-018-0150-3. eCollection 2018. PMID:30272026[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Aso Y, Nagao J, Koga H, Okuda K, Kanemasa Y, Sashihara T, Nakayama J, Sonomoto K. Heterologous expression and functional analysis of the gene cluster for the biosynthesis of and immunity to the lantibiotic, nukacin ISK-1. J Biosci Bioeng. 2004;98(6):429-36. PMID:16233732 doi:http://dx.doi.org/S1389-1723(05)00308-7
- ↑ Asaduzzaman SM, Nagao J, Aso Y, Nakayama J, Sonomoto K. Lysine-oriented charges trigger the membrane binding and activity of nukacin ISK-1. Appl Environ Microbiol. 2006 Sep;72(9):6012-7. PMID:16957223 doi:http://dx.doi.org/72/9/6012
- ↑ Fujinami D, -Mahin AA, Elsayed KM, Islam MR, Nagao JI, Roy U, Momin S, Zendo T, Kohda D, Sonomoto K. The lantibiotic nukacin ISK-1 exists in an equilibrium between active and inactive lipid-II binding states. Commun Biol. 2018 Sep 25;1:150. doi: 10.1038/s42003-018-0150-3. eCollection 2018. PMID:30272026 doi:http://dx.doi.org/10.1038/s42003-018-0150-3
|
